Cerebral Therapeutics Inks $40M Series C
Summary
AURORA, CO, Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding. Cerebral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for refractory neurological diseases. Founded by experts in the fields of neuroscience, neurosurgery, and drug delivery, the Company is pioneering intracerebroventricular (ICV) therapies for people with neurological diseases. Its investigational drug therapies and companion biomarker strategies are enabled by the Companys proprietary technology that enables precise targeted delivery to the central nervous system. Cerebral Therapeutics ICV infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral medications are not able to achieve adequate control and/or are limited by systemic toxicities.